The DOI matches its Crossref record; 103 of the 108 references it cites were found in a registry or an index.
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of 30,000 patients a year worldwide. The median reported survival time since onset ranges from 24 to 48 months. Riluzole is the only currently approved mildly efficacious treatment. Riluzole received marketing authorization in 1995 in the USA and in 1996 in Europe. In the years that followed, over 60 molecules have been investigated as a possible treatment for ALS. Despite significant research efforts, the overwhelming majority of human clinical trials (CTs) have failed to demonstrate clinical efficacy. In the past year, oral masitinib and intravenous edaravone have emerged as promising new therapeutics with claimed efficacy in CTs in ALS patients. Given their advanced phase of clinical development one may consider these drugs as the most likely near-term additions to the therapeutic arsenal available for patients with ALS. In terms of patient inclusion, CT with masitinib recruited a wider, more representative, less restrictive patient population in comparison to the only successful edaravone CT (edaravone eligibility criteria represents only 18% of masitinib study patients). The present manuscript reviews >50 CTs conducted in the last 20 years since riluzole was first approved. A special emphasis is put on the analysis of existing evidence in support of the clinical efficacy of edaravone and masitinib and the possible implications of an eventual marketing authorisation in the treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple small molecules with anti-inflammatory activity, including minocycline, masitinib, NP001, and celecoxib, have been tested for the treatment of ALS. Although most have failed, masitinib was found to be effective in the preceding clinical trials, and a Phase III clinical trial testing masitinib in ALS patients is ongoing.577”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [577]
Experimental — accuracy not yet measuredIn the citing paper
“Probiotics are considered to be dietary factors that can influence the human intestinal microbiota, which can affect the composition and structure of the intestinal flora; which, in turn, plays a role in protecting the intestinal epithelial barrier, inhibiting pathogen production, and regulating the immune system (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
In the citing paper
“Through use of probiotics, the number of SCFA-producing microorganisms in the intestine can be increased (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,239
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,303
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Jd, M., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 910
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Flagged first, then by citations
5 of the 108 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi Laterale), 2014, ALS Clinical Trials List.
- Bradley, 1995, A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS., Ann. Neurol., 38
- Rosenfeld, 2001, “Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results,” in Proceedings of the, American Academy of Neurology Annual Meeting
- Teva, 2010, News Release.
- Tohgi, 1999, Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis., Ann. Neurol., 46, 129, 10.1002/1531-8249(199907)46:1129::AID-ANA213.0.CO;2-Y · DOI
Cited by
Sorted by citations
Items 401–451 of 451
Impact of aging on the central nervous system: Approaches for antiaging
Yavaş, G., & Mut, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98804-9.00023-2
Selection of animal models for drug efficacy
Veening-Griffioen, D. H. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1605
An Understanding of Different Mechanisms Leading to Neurodegenerative Diseases
Sami, D. G., & Salama, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_10-1
Levamisole Derivatives As Immune Modulators for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Baugh, S. D. P., Morrice, J. R., Reitz, A. B., Shaw, C. A., & Gregory, C. Y. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0028
Blood Markers of Oxidative Stress in Patients with Amyotrophic Lateral Sclerosis
Hassan, S., Eid, M., Hassan, A., & Hayek, S. E. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-1513-2_8
ESCLEROSE LATERAL AMIOTRÓFICA (ELA): MECANISMOS, DIAGNÓSTICO E POSSÍVEIS TRATAMENTOS
Diniz, M. C. O. P., dos Santos, A. M., Lula, B. G. G. G. T., Peixoto, F. P., Alves, F. L. N., Valadares, G. P., de Siqueira, Í. C. A., Bastos, I. R., de Araújo, L. M. F. T., Carvalho, L. G., et al. (2023) · Revista Foco · doi:10.54751/revistafoco.v16n5-058
Seong, J., Chun, C., Smith, A. S. T., Joo, J., & Mack, D. L. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.113275
Roberts, E. (2023) · EMJ Neurology · doi:10.33590/emjneurol/10300734
Reis, A. L. G. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-07052024-162252
Novel therapeutics for diverse neurodegenerative disorders
Chaurasia, R. N., & Favas, T. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00051-6
Role of pharmacotherapy in the treatment of amyotrophic lateral sclerosis
Betík, A., & Vlčková, E. (2024) · Klinická farmakologie a farmacie · doi:10.36290/far.2024.011
Acute viral infection accelerates neurodegeneration in a mouse model of ALS
Marzok, A., Mapletoft, J., Ahmed, I., Cowbrough, B., Celeste, D. B., D’Agostino, M. R., Ang, J. C., Chen, A., Surendran, V., Tugg, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77353-y · Cited by 1
An Understanding of Different Mechanisms Leading to Neurodegenerative Diseases
Sami, D. G., & Salama, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_10
Blood markers of oxidative stress in patients with amyotrophic lateral sclerosis
Hassan, S., Eid, M., Hassan, A., & Hayek, S. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00018-x
Loopomics: A possible breakthrough in the understanding and control of life
Burlando, B. (2025) · PNEI REVIEW · doi:10.3280/pnei2025oa19417
Riluzol - Um Surto de Luz para Pacientes com ELA
Monteiro, D., Pinto, R., & Neto, R. (2025) · Boletim da Sociedade Portuguesa de Química · doi:10.52590/m3.p720.a30002968
iPS Cell Drug Discovery for Amyotrophic Lateral Sclerosis (ALS)
Morimoto, S., Takahashi, S., & Okano, H. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.996
Budianto, P., Mirawati, D. K., Benedictus, B., Tan, K., Hafizhan, M., & Putra, S. E. (2025) · MNJ (Malang Neurology Journal) · doi:10.21776/ub.mnj.2025.011.01.13
Neurological Disorders and Motor Dysfunction: A Biomedical Approach to Movement Impairment
(2025) · International Journal of Progressive Research in Engineering Management and Science · doi:10.58257/ijprems43336
Bone Marrow-Derived Cells with GLT1 Gene Delivery for Amyotrophic Lateral Sclerosis
Ohashi, N., & Terashima, T. (2025) · Neuromethods · doi:10.1007/978-1-0716-4783-7_6
There is no known cure for ALS, but medical tourism exploits desperation for profit
Illes, J., & Pioro, E. P. (2025) · doi:10.64628/aam.m7ejduhy7
My Amyotrophic Lateral Sclerosis (ALS) Journey from Weakness to Diagnosis: A Journey of Hope
Wityshyn, S., Sanghai, N., & Tranmer, G. K. (2025) · Healthcare · doi:10.3390/healthcare13212754
Protti, M., Lecce, R. D., Adamec, J., Regazzoni, L., Valsecchi, V., Volpi, C., Mandrioli, R., & Mercolini, L. (2025) · Journal of Pharmaceutical and Biomedical Analysis Open · doi:10.1016/j.jpbao.2025.100094
Genin, E. C., Lespinasse, F., Mauri-Crouzet, A., Dupuis, L., & Paquis‐Flucklinger, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210852
Gut Microbiota and Amyotrophic Lateral Sclerosis
Vahabzadeh, G., & Golab, F. (2025) · The Neuroscience Journal of Shefaye Khatam · doi:10.61882/shefa.14.1.117
Aragón-González, A., Shaw, A. C., Kok, J. R., Roussel, F. S., Santos Souza, C. D., Granger, S. M., Vetter, T. A., de Diego, Y., Meyer, K., Beal, S. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25591279
Aragón-González, A., Shaw, A. C., Kok, J. R., Roussel, F. S., Santos Souza, C. D., Granger, S. M., Vetter, T. A., de Diego, Y., Meyer, K., Beal, S. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25591483
Curtis, S. E., Tatlock, S., O’Hara, L., Seçinti, E., Mehdiyoun, N. F., Ayala‐Nunes, L., Flynn, J., Fernelius, K., Hodson, N., & Delbecque, L. (2025) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2025.2604233
Artificial Intelligence and Neuromuscular Diseases: A Narrative Review
Wunsch, D. C., Hier, D. B., & Wunsch, D. C. (2026) · AI in Medicine · doi:10.3390/aimed1010005
Lee, M.-H., Li, W. H., Sampson, K., Choi, S. H., Jones, M., Steiner, J. P., & Nath, A. (2026) · Brain · doi:10.1093/brain/awag102
Li, R., Wang, L., Bu, W., Zhang, X., Li, X. J., Li, J., Shen, J., Li, J., & Cai, Z. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1784115
Hergesheimer, R. C. (2021) · theses.fr (ABES) · doi:10.70675/89c77c60z44efz4d20z9890z4c8df03030ad
Woodard, G. E. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106161
Kumawat, A., Soni, K., Saxena, S., & Jain, A. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70832
Zhang, M., Yang, W., Wang, J., Zou, B., Zheng, J. C., Wu, Q., & 高革 (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2664985
Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025
Konstantinova, P. S., Townhill, J., Bronzova, J., Andreeva, V., Sathe, S. S., & Sampaio, C. (2026) · Movement Disorders · doi:10.1002/mds.70361 · Cited by 1
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44367-1.00006-4
Travis, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44367-1.00010-6
The centrosome-cilium-centriolar satellite axis in neurodegenerative diseases
Şahin, U., & Firat‐Karalar, E. N. (2026) · EMBO Reports · doi:10.1038/s44319-026-00877-3
Sanghai, N., Kelley, R., Lao, Y., Madlangsakay, M. I. R., Paul, P., Llanes-Cuesta, M. A., Wang, J.-F., Zahedi, R. P., Kong, J., & Tranmer, G. K. (2026) · Advanced Science · doi:10.1002/advs.76432
Guth, M. A. S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104752
van de Zande, N. A., Ruiter, C. C. C., Polman, M. A., Brama, S. C. M., Roos, R. A. C., Kremer, P. H. C., & de Bot, S. T. (2026) · Brain Communications · doi:10.1093/braincomms/fcag289
Nam, M., Oh, Y., Choi, Y., Lee, J., Jeong, G. H., Park, S., Yoo, S.-A., Kim, M., Kang, S., & Rhim, H. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00977
Viljoen, S. J., Chaves, J. C. S., Peall, I. W., White, A. R., & Oikari, L. E. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126168
Steyn, F. J., Pilkar, R. B., Sethi, N., Heller, L., Holdom, C. J., van Eijk, R. P. A., Strączkiewicz, M., Burke, K. M., Berry, J. D., Chandriani, S. J., et al. (2026) · Journal of Medical Internet Research · doi:10.2196/106677
Patel, M., Das, S., Kumari, A. P., & Kumar, A. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06209-9
Positive allosteric modulators of AMPA receptors: advances and emerging trends
Colson, T., Pirotte, B., & Francotte, P. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2748595
DNA methylation in motor neuron biology and epigeneticopathy in amyotrophic lateral sclerosis
MARTIN, L. J. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19043-8.00014-1
Metadata
- Authors
- Petrov, D., Mansfield, C., Moussy, A., & Hermine, O.
- Affiliations
- AB Science (France) (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Hermine, Olivier
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-03-22
- Volume
- 9
- Pages
- 68-68
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC5360725
- OpenAlex
- W2597399186
- Cited by
- 451
- References
- 108
- Citations by year
- 2026: 28 · 2025: 41 · 2024: 45 · 2023: 46 · 2022: 65 · 2021: 63 · 2020: 53 · 2019: 52 · 2018: 50 · 2017: 8
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0051)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- amyotrophic lateral sclerosis, clinical trial failure, riluzole, edaravone, masitinib, drug development, clinical efficacy, patient selection criteria, drug approval, neurodegenerative disease therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
